|
1）Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol. 2007; 137: 87-98
|
|
|
|
2）Deeg HJ. How I treat refractory acute GVHD. Blood. 2007; 109: 4119-26
|
|
|
|
|
|
3）Ferrara JL, Levine JE, Reddy P. Graft-versus-host disease. Lancet. 2009; 373: 1550-61
|
|
|
|
|
|
4）Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363: 1439-41
|
|
|
|
|
|
5）Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006; 81: 1390-7
|
|
|
|
|
|
6）Fang B, Song Y, Liao L, et al. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc. 2007; 39: 3358-62
|
|
|
|
|
|
7）Müller I, Kordowich S, Holzwarth C, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008; 40: 25-32
|
|
|
|
|
|
8）Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; 371: 1579-86
|
|
|
|
|
|
9）Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009; 15: 804-11
|
|
|
|
|
|
10）von Bonin M, Stölzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009; 43: 245-51
|
|
|
|
|
|
11）Lucchini G, Introna M, Dander E, et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant. 2010; 16: 1293-301
|
|
|
|
|
|
12）Martin P, Uberti JP, Soiffer RJ, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant. 2010; 16(Suppl 2): S169-170
|
|
|
|
|
|
13）Szabolcs P, Visani G. Locatelli F, et al. Treatment of steroid-refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase III randomized, placebo-controlled study. Biol Blood Marrow Transplant. 2010; 16(Suppl 2): S298
|
|
|
|
|
|
14）Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 2011; 17: 534-41
|
|
|
|
|
|
15）Pérez-Simon JA, López-Villar O, Andreu EJ, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica. 2011; 96: 1072-6
|
|
|
|
|
|
16）Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Int J Hematol. 2012; 95: 182-8
|
|
|
|
|
17）Muroi K, Miyamura K, Ohashi K, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013; 98: 206-13
|
|
|
|
|
|
18）Ball LM, Bernardo ME, Roelofs H, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013; 163: 501-9
|
|
|
|
|
|
19）Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014; 20: 1580-5
|
|
|
|
|
|
20）Kurtzberg J, Prockop S, Teira P, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant. 2014; 20: 229-35
|
|
|
|
|
|
21）Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014; 20: 375-81
|
|
|
|
|
|
22）Watakabe K, Miyamura K, Ozawa Y, et al. Efficacy of mesenchymal stem cells for the treatment of steroid-refractory aGVHD. Blood. 2014; 124: 3913
|
|
|
|
|
|
23）Kurtzberg J, Prockop SE, Prasad VK, et al. Treatment with human mesenchymal stem cells (Remestemcel-L) is effective in pediatric patients with refractory acute graft versus host disease. BMT Tandem Meetings, 2015 February 14, Abstract 492
|
|
|
|
|
|
24）Sharma RR, Pollock K, Hubel A, et al. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion. 2014; 54: 1418-37
|
|
|
|
|
|
25）Kaipe H, Erkers T, Sadeghi B, et al. Stromal cells-are they really useful for GVHD? Bone Marrow Transplant. 2014; 49: 737-43
|
|
|
|
|
|
26）Newell LF, Deans RJ, Maziarz RT. Adult adherent stromal cells in the management of graft-versus-host disease. Expert Opin Biol Ther. 2014; 14: 231-46
|
|
|
|
|
|
27）Gouveia de Andrade AV, Bertolino G, Riewaldt J, et al. Extracellular vesicles secreted by bone marrow- and adipose tissue-derived mesenchymal stromal cells fail to suppress lymphocyte proliferation. Stem Cells Dev. 2015; 24: 1374-6
|
|
|
|
|